Connect Biopharma (CNTB) vs MiNK Therapeutics (INKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MiNK Therapeutics (INKT) has outperformed Connect Biopharma (CNTB) over the past year, losing 24.6% versus a loss of 51.6%. Over five years, INKT leads with a -90.8% price change compared with -94.9% for CNTB. Connect Biopharma is the larger company by market cap ($56.9 million vs $55.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTB | INKT |
|---|---|---|
| Share price | $0.9043 | $10.88 |
| Market cap | $56.95M | $55.52M |
| 1-day change | +2.67% | -1.09% |
| YTD return | -68.77% | -1.35% |
| 1-year return | -51.61% | -24.61% |
| 5-year return | -94.87% | -90.83% |
| EPS (TTM) | $-1.19 | $-2.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.82 | $16.93 |
| 52-week low | $0.85 | $8.48 |
| Distance from 52-week high | -76.33% | -35.72% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +550.23% | +258.46% |
| Average volume | 3.81M | 13.80K |
| Shares outstanding | 62.97M | 5.10M |
| Employees | 64 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INKT has outperformed CNTB by 27.0 percentage points over the past year.
About Connect Biopharma
CNTB stock →Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).
Health Care · Biotechnology: Pharmaceutical Preparations · 64 employees
About MiNK Therapeutics
INKT stock →MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees
CNTB vs INKT FAQ
Which is bigger, Connect Biopharma or MiNK Therapeutics?
Connect Biopharma (CNTB) is larger, with a market capitalization of $56.95M compared with $55.52M for MiNK Therapeutics (INKT).
Which stock has performed better over the past year, CNTB or INKT?
INKT returned -24.61% over the past 12 months, compared with -51.61% for CNTB (price return, excluding dividends). Past performance does not predict future results.
Are Connect Biopharma and MiNK Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Connect Biopharma and Biotechnology: Biological Products (No Diagnostic Substances) for MiNK Therapeutics.